Biochip Surface Layer Reducing Non-Specific Adsorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biochips face issues with non-specific protein adsorption, leading to reduced detection accuracy over time due to increased non-specific adsorption and elution of surface layer components.
Innovation Solution
A medical device with a surface layer made from a cured product of a compound containing a biocompatible group and an alkoxysilyl group, applied on an inorganic substrate, which reduces non-specific adsorption and enhances durability by minimizing elution from the surface layer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a cured material layer made of copolymer of MPC and BMA is formed on the substrate, then non-specific adsorption amount is reduced, but non-specific adsorption increases and detection accuracy deteriorates when used for a long period of time
Solution Approach 1:
The invention uses a composite material consisting of polyoxyethylene polyol or polyoxyethylene alkyl ether combined with alkoxysilyl group-containing compound. This composite structure provides both the non-specific adsorption reduction capability of polyoxyethylene and the durability of alkoxysilyl groups that form strong bonds with the substrate, preventing elution even after long-term use.
Solution Approach 2:
The invention specifies precise compositional parameters: polyoxyethylene units with n=1-300, alkoxysilyl group content of 2-70% by mass, and biocompatible group content of 25-83% by mass. These parameter optimizations ensure the surface layer maintains low non-specific adsorption and high durability simultaneously.
2Quantity of substance
If a cured layer is formed by coating with silane coupling agent and radically polymerizing with acrylamide, then non-specific adsorption amount is reduced, but components of the cured layer are eluted when used for a long period of time
Solution Approach 1:
The alkoxysilyl group acts as an intermediary that forms strong chemical bonds between the polyoxyethylene-based surface layer and the inorganic substrate. This intermediary bonding mechanism prevents elution of surface layer components while maintaining low non-specific adsorption properties.
Solution Approach 2:
The invention creates a surface layer with localized functional groups: polyoxyethylene units at the surface provide non-specific adsorption reduction, while alkoxysilyl groups near the substrate interface provide strong bonding. This spatial differentiation of functions achieves both low adsorption and high stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively reduces non-specific adsorption, maintains detection accuracy over time, and improves the durability of the biochip surface, as evidenced by low total organic carbon (TOC) elution after immersion in water.
Implementation Method 1
a surface layer which is made of a cured product of a compound having a biocompatible group and an alkoxysilyl group
Implementation Method 2
a surface layer which is made of a cured product of a compound having a biocompatible group and an alkoxysilyl group
Implementation Method 3
non-specific proteins other than the biological substance to be detected will be adsorbed to portions where the molecules to capture the biological substance are not fixed
Data Source
AI summary
A medical device where the non-specific absorption amount is reduced, durability is excellent, and eluents from the surface layer are reduced. The medical device includes a device substrate and a surface layer provided on at least part of the surface of the device substrate in contact with water, where the part of the surface of the device substrate is made of an inorganic material, the surface layer is made of a cured product of a compound having a biocompatible group and an alkoxysilyl group, the content of the biocompatible group in the compound is from 25 to 83% by mass, and the content of the alkoxysilyl group is from 2 to 70% by mass.